🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

1/ 🚨 New paper alert! Across 2 studies (N = 1,257) using a panel service to get more representative samples, we compared psychedelics experiences to cannabis ones in terms of both immediate and long-term risks and benefits. Here's what we discovered! 👇 journals.sagepub.com/eprint/QPYJ75V…

Please re-share to support our important research on psychedelic experiences among Veterans!

Commentary: A framework for assessment of adverse events in psychedelic research - Katherine Cheung, Rebecca Ehrenkranz, Jared Hinkle, David Yaden, 2024 | Journal of Psychopharmacology journals.sagepub.com/doi/full/10.11…

In response to Palitsky et al’s helpful article proposing a framework for the assessment of psychedelic adverse events (AE), David B. Yaden, Rebecca Ehrenkranz, PhD, MPH, @jaredhinkle4 and I offer some thoughts on feasibility, AE assessment standards & reporting related to issues they discuss (1/n)

Thrilled to be able to share this, in an amazing issue on psychedelic ethics! A wonderful set of articles and commentaries: tandfonline.com/toc/uajb20/25/1

Are you local to Baltimore and interested in public science communication about psychedelics? If so, consider attending this talk by CPCR Faculty David Yaden (David B. Yaden) on the science of psychedelic and psychedelic-like experiences, including risks and benefits.

Do you know anyone with chronic back pain? Has it caused other issues, such as depression, social withdrawal, unemployment, and/or substance use? I am conducting an NIH funded clinical trial to help determine whether psilocybin can help to break this downward spiral and how

We analyzed 2 decades of materials used in psilocybin trials. We examined how “set and setting” is communicated to participants pre- psychedelic sessions. Most content is about bio, psych, and social safety–but we also draw attention to some potentially unintentional expectancies

Join the world’s premier psychedelic research center! My lab at Johns Hopkins Psychedelic Research Center is hiring 3 Research Program Coordinators. We're looking for talented, hard-working, rigorous emerging scientists to contribute to scientific studies, including psychedelic admin trials. Links:

CPCR postdoc Rebecca Ehrenkranz (Rebecca Ehrenkranz, PhD, MPH) will be presenting a poster at the Perspectives on Scientific Error workshop in Bern! Her presentation will focus on strategies to increase independence in research and reduce bias in psychedelic studies. errorsin.science

Excited to announce a clinic for individuals experiencing difficulties following a psychedelic experience. I believe this is the first clinic of its kind in the US and is right here at Johns Hopkins Medicine, where we aim to learn about & address the benefits & risks of psychedelics 🧵

For anyone in Baltimore - I'm excited to participate on a panel about science communication this Thursday co-sponsored by Baltimore Underground Science Space (BUGSS) and Maryland Institute College of Art, and I hope to see you there!

We want to hear your opinions about clinical trial research! What are the reasons you might not be able to join a clinical trial? We are conducting a survey study to understand concerns and challenges related to clinical trial participation, including factors influencing

🎉NEW PAPER ALERT🎉In an RCT, we found no difference between psilocybin and placebo in alcohol use characterstics in a relapse prevention framework for AUD patients. So excited to finally share these findings! sciencedirect.com/science/articl…

New paper 🧵! Rebecca Ehrenkranz, PhD, MPH, David B. Yaden & I explore investigator-level biases in psychedelic clinical trials, & measures that have been proposed to mitigate them. We advocate for 4 additional measures that we believe may be particularly beneficial for the field to implement

🚨Postdoc Opportunity in Psychedelic Science Join a leading psychedelic research team at Johns Hopkins (Johns Hopkins Psychedelic Research Center). Design and lead experimental studies & clinical trials. w/ D Yaden (David B. Yaden) & S Nayak (Sandeep Nayak) -Salary: Middling -Apply: [email protected] -Pls share!

New in Research Ethics: "Enhanced independence: De-biasing processes in psychedelic research and beyond" RCTs aren't immune to bias—and perceived bias in psychedelic trials is an issue. Katherine Cheung Rebecca Ehrenkranz, PhD, MPH @existwell propose 4 independence-enhancing practices: -

Join our brain stimulation research study! Researchers at Johns Hopkins are investigating the effects of psilocybin—a psychoactive compound found in mushrooms—on brain activity and function using transcranial magnetic stimulation, EEG, fMRI, and cognitive testing. Scan the QR

Thrilled to connect at the Neurobiology of Psychedelics Gordon Research Conference (Gordon Research Conferences) next week! CPCR researchers and fellow scientists will discuss wide range of topics, including preclinical and clinical research, drug discovery, and neuroplasticity.

New paper thread! 🧵 Many have called for “enhanced” informed consent documents (ICD) for psychedelic research & treatments, with growing calls for tailored ICDs in the psychedelic bioethics lit. But how closely do ICDs in psychedelic clinical trials reflect these proposals?